Biocon gains as US FDA approves Perjeta biosimilar
In short
Biocon shares rose after the US FDA approved its biosimilar to Perjeta. The medicine is for patients with metastatic and early-stage HER2-positive breast cancer, and Biocon expects a US launch in Q3 2028.
It could strengthen Biocon’s cancer drug business.
What the reporting says
Biocon’s shares gained after the US FDA approved its biosimilar to Perjeta for patients with metastatic and early-stage HER2-positive breast cancer. The approval expands the company’s oncology biosimilar pipeline and sets up a future US launch.
Why it matters
Biocon has received US FDA approval for a biosimilar to Perjeta, covering patients with metastatic and early-stage HER2-positive breast cancer. The company expects to launch the drug in the US in Q3 2028 under its licensing agreement with Genentech. The approval is significant for Biocon’s biosimilar portfolio and may support its oncology business.